FLAIR: Week 124 Results of Long-Acting Injectable Cabotegravir + Rilpivirine

July 18-21, 2021; Virtual
At Week 124, 80% of patients still demonstrated virologic suppression on monthly injectable cabotegravir + rilpivirine, with no new safety signals since the Week 96 analysis.
Format: Microsoft PowerPoint (.ppt)
File Size: 257 KB
Released: July 21, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Silvia Petretti on individualizing antiretroviral therapy according to patient factors from Clinical Care Options

person default Silvia Petretti Released: October 22, 2021

Clinical Care Options (CCO) expert analysis of new HIV data from IDWeek 2021, provided by expert HIV faculty

Eric S. Daar, MD Released: October 21, 2021

Expert selections of important HIV data from IDWeek 2021, including current and investigational ART, HIV PrEP, and metabolic outcomes of ART.

Eric S. Daar, MD Darcy Wooten, MD Released: October 19, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue